Allogene Therapeutics ALLO Cash Flow Statement (2018-2026)

NASDAQ ALLO
$0.90 -0.03 (-3.41%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Allogene Therapeutics Quarterly Cash Flow Statement

Periods 35 quarters
Latest Sep 2026

Allogene Therapeutics reported cash from operations of -$36.12M and free cash flow of -$39.44M for the quarter ended Sep 2026, down 21.7% year over year. This cash flow statement covers 35 quarters of results from Mar 2018 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
0.09M-78.61M-80.29M-84.24M-97.28M-99.97M-79.23M-62.29M-85.78M-65.00M-66.36M-66.29M-59.73M-50.94M-41.40M-38.81M-42.61M-42.68M-50.37M
Depreciation and DepletionDep. & Depletion
4.24M3.69M3.68M3.86M3.07M3.51M3.64M3.57M3.48M3.56M3.10M3.11M3.10M3.06M2.87M2.65M2.59M
Depreciation, Depletion & Amortization
Amortization of IntangiblesAmort. of Intangibles
Depreciation & Amortization (CF)Dep. & Amort.
4.24M3.69M3.68M3.86M3.07M3.51M3.64M3.57M3.48M3.56M3.10M3.11M3.10M3.10M2.87M2.65M2.59M
Share-based CompensationStock Comp.
22.04M22.32M22.89M21.15M17.25M18.77M16.59M15.35M15.23M11.92M12.18M8.69M8.65M8.13M8.27M12.44M7.03M
Deferred Taxes
Gains from Equity InvestmentsGains Equity
-5.86M-2.54M-3.99M-2.72M-3.64M-2.94M-2.44M-2.50M-2.81M-0.93M
Asset Writedowns and ImpairmentWritedown
-3.96M10.25M4.99M10.73M2.38M0.02M
Other non-cash itemsOther Non-Cash
1.58M1.80M2.08M1.05M0.40M0.72M-0.92M1.65M-1.60M-1.64M-0.18M-0.02M0.11M0.23M0.18M-0.23M-0.61M
Change in Working Capital
Change in Account PayablesChange Payables
-2.04M-0.51M1.42M1.01M2.94M1.06M-4.29M-3.97M-0.30M-0.12M-0.34M-0.42M-1.07M0.60M0.66M1.03M2.81M
Change in Accrued ExpensesChange Accrued Exp.
-2.77M-9.05M5.71M1.95M3.14M5.69M-0.08M-12.72M0.29M-5.69M-5.22M1.74M1.09M-0.12M-5.10M2.28M3.72M
Change in Other Operating AssetsOther Assets Change
-5.70M9.79M1.53M-5.30M-5.21M-1.31M0.00M-1.82M3.50M-1.36M1.07M1.91M-1.34M-0.88M-24.70M1.16M-0.40M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.85M-0.60M-0.44M-0.43M-0.43M-0.63M0.01M-4.44M-1.55M-1.20M-1.67M-1.64M-1.50M-1.56M-1.89M-1.69M-1.68M
Other Working Capital ChangesOther WC Changes
4.85M-10.39M-1.97M4.87M4.78M0.68M0.01M-2.62M-5.06M0.16M-2.74M-3.55M-0.16M-0.68M22.81M-2.84M-1.28M
Cash from OperationsCash from Ops.
-45.44M-68.24M-42.53M-47.66M-62.10M-66.64M-61.86M-55.53M-53.71M-55.90M-52.93M-39.03M-29.69M-27.60M-12.91M-32.00M-36.12M
Investing Activities
Capital ExpendituresCapex
2.69M3.88M3.38M2.85M4.63M4.00M3.31M3.04M3.22M3.08M3.33M3.34M3.41M3.24M3.24M3.45M3.32M
Change in Property, Plant and EquipmentChange in PP&E
-2.69M-3.88M-3.38M-2.85M-4.63M-4.00M-3.31M-3.04M-3.22M-3.08M-3.33M-3.34M-3.41M-3.24M-3.24M-3.45M-3.32M
Purchase of InvestmentsInvestments Purchased
52.55M89.16M61.71M49.45M47.79M35.09M135.42M199.41M68.70M81.13M50.23M9.92M49.73M28.38M101.69M183.72M46.06M
Sale and Maturity of InvestmentsInvestments Sold
810.93M68.68M117.12M74.58M99.08M149.06M152.87M165.16M136.34M103.27M56.50M53.80M61.91M61.99M72.12M36.31M72.20M
Cash from Investing ActivitiesCash from Investing
29.25M-22.38M54.03M24.91M49.60M112.94M17.16M-34.27M67.46M22.13M6.18M43.84M11.94M33.61M-29.59M-147.56M26.12M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt RepaymentsLT Debt Repayment
-1.96M-1.98M-2.00M-2.62M-2.94M-2.97M-3.02M-3.02M-3.04M-3.07M-3.23M-3.29M-3.17M-3.24M-3.23M-3.30M-3.29M
Net Long-Term Debt Issued (Repaid)Net LT Debt
1.96M1.98M2.00M2.62M2.94M2.97M3.02M3.02M3.04M3.07M3.23M3.29M3.17M3.24M3.23M3.30M3.29M
Net Debt Issuances and RepaymentsNet Debt Issuance
1.96M1.98M2.00M2.62M2.94M2.97M3.02M3.02M3.04M3.07M3.23M3.29M3.17M3.24M3.23M3.30M3.29M
Change in Capital Stock
Common Stock IssuedStock Issued
0.32M1.81M0.02M1.07M0.05M1.73M1.61M1.09M0.16M1.65M0.64M0.26M0.45M0.65M
Net Shares Issued and RepurchasedNet Shares Issued
0.32M1.81M0.02M1.07M0.05M1.73M1.61M1.09M0.16M1.65M0.64M0.26M0.45M0.65M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.32M1.81M0.02M1.07M0.05M1.73M1.61M1.09M0.16M1.65M0.64M0.26M0.45M0.65M
Other financing activities (as filed)
3.35M3.56M
Cash from Financing ActivitiesCash from Financing
0.32M1.81M0.02M1.07M0.05M1.73M89.52M4.29M0.16M1.65M13.99M5.07M3.24M7.86M21.12M187.87M0.65M
Additional items
Change in Cash
-15.86M-88.80M11.53M-21.68M-12.45M48.03M44.83M-85.51M13.91M-32.12M-32.76M9.88M-14.52M13.87M-21.38M8.32M-9.36M
Ending Cash Balance
183.61M94.81M106.33M84.65M72.20M120.22M165.05M79.54M93.45M61.33M180.96M61.53M85.51M52.75M62.62M48.11M61.98M40.60M48.92M39.56M
Free Cash FlowFCF
-48.13M-72.12M-45.91M-50.50M-66.72M-70.64M-65.17M-58.57M-56.92M-58.98M-56.26M-42.37M-33.10M-30.84M-16.16M-35.44M-39.44M
Net Cash FlowNCF
-15.86M-88.80M11.53M-21.68M-12.45M48.03M44.83M-85.51M13.91M-32.12M-32.76M9.88M-14.52M13.87M-21.38M8.32M-9.36M

Allogene Therapeutics Cash Flow Statement API

Pull Allogene Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ALLO&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY